<SEC-DOCUMENT>0001213900-25-116693.txt : 20251201
<SEC-HEADER>0001213900-25-116693.hdr.sgml : 20251201
<ACCEPTANCE-DATETIME>20251201161511
ACCESSION NUMBER:		0001213900-25-116693
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251201
DATE AS OF CHANGE:		20251201

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clearmind Medicine Inc.
		CENTRAL INDEX KEY:			0001892500
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93839
		FILM NUMBER:		251539829

	BUSINESS ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5
		BUSINESS PHONE:		972-54-5704749

	MAIL ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Capitalink Ltd.
		CENTRAL INDEX KEY:			0002036836
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		RAOUL WALLENBERG 20
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-505-501574

	MAIL ADDRESS:	
		STREET 1:		RAOUL WALLENBERG 20
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Capitalink Ltd. -->
          <cik>0002036836</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Shares, no par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>11/19/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001892500</issuerCik>
        <issuerName>Clearmind Medicine Inc.</issuerName>
        <issuerCusip>185053402</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>101 - 1220 West 6th Avenue,</com:street1>
          <com:city>Vancouver</com:city>
          <com:stateOrCountry>A1</com:stateOrCountry>
          <com:zipCode>V6H1A5</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Capitalink Ltd.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>L3</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>3307291.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>3307291.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3307291.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>*Percentage calculated based on 33,106,024 common shares, no par value per share, of Clearmind Medicine Inc. (the "Issuer") issued and outstanding, as reported by the Issuer in prospectus supplement filed pursuant to Rule 424(b)(5) as filed with the Securities and Exchange Commission on November 19, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Clearmind Medicine Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>101 - 1220 West 6th Avenue, Vancouver, British Columbia V6H1A5</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Capitalink Ltd.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>20 Raoul Wallenberg Street, Tel Aviv, Israel 6971916</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Israel</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</amountBeneficiallyOwned>
        <classPercent>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Capitalink Ltd.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Lavi Krasney</signature>
        <title>Chief Executive Officer</title>
        <date>12/01/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
